FOXO4-DRI
A senolytic peptide designed to selectively clear senescent cells by disrupting the FOXO4-p53 interaction, studied for anti-aging applications.
One famous 2017 Cell paper, nine years, and still not a single human trial. FOXO4-DRI works by freeing p53 from the FOXO4 protein that keeps senescent cells alive, and the mouse data are genuinely interesting — restored fur density, renal function and running-wheel activity in a fast-ageing strain, plus five independent labs replicating its effects in lung fibrosis, tumour radiosensitisation, aged testis and aorta. But the same mechanism has a published cost: in Circulation in 2023, clearing senescent cells with FOXO4-DRI made pulmonary hypertension worse in mice by destroying pulmonary endothelial cells. That is not off-target toxicity — it is the drug working as designed in a tissue where senescent cells were load-bearing. There is no human dose, no measured half-life in any species, and the published mouse route is intravenous or intraperitoneal, not the subcutaneous injection sold online.
What is FOXO4-DRI?
FOXO4-DRI is a modified peptide designed to target and eliminate senescent cells — aged cells that no longer divide but release inflammatory signals that damage surrounding tissue. By disrupting the interaction between FOXO4 and p53 proteins, it may trigger senescent cells to undergo programmed cell death (apoptosis) while leaving healthy cells unaffected.
What FOXO4-DRI Is Investigated For
FOXO4-DRI is investigated as a senolytic peptide designed to selectively clear senescent cells by disrupting the FOXO4-p53 interaction, with proposed applications in age-related tissue decline, inflammation, and functional restoration in aging. The strongest evidence is the 2017 Cell paper from Peter de Keizer's group at Erasmus MC reporting that aged and chemotherapy-treated mice showed restoration of physical fitness, fur density, and renal function after FOXO4-DRI treatment, along with additional preclinical work in keloid fibroblasts, pulmonary fibrosis, aged Leydig cells, and in vitro chondrocytes. The replication picture is stronger than the page used to imply: at least five groups sharing no authors with the original lab have reproduced senolytic effects in vivo — two separate bleomycin lung-fibrosis replications, one of which benchmarked the peptide against the approved antifibrotic pirfenidone and found comparable effects on senescent-cell burden, SASP expression and collagen deposition; NSCLC radiosensitisation; a neonatal hyperoxic lung-injury model; and aortic ageing in both naturally aged and progeroid mice. Two threads have extended that picture since: a 2024 Experimental Gerontology study reported that FOXO4-DRI improved sperm quality and spermatogenesis in naturally aged mice by reducing SASP secretion from Leydig cells, adding a fertility endpoint to the earlier testosterone work, and a separate oncology thread has been running since 2021, using the peptide as a radiotherapy and chemotherapy adjuvant — a JCI Insight study that year reported FOXO4-DRI radiosensitising non-small-cell lung cancer in vitro and in vivo while also alleviating radiation-induced pulmonary fibrosis, and a 2026 Molecular Carcinogenesis paper used it as one of two tool compounds to show that clearing temozolomide-induced senescent glioblastoma cells improves chemotherapy efficacy. The honest caveats are overwhelming: no human clinical trial of any phase has been conducted nearly a decade after the foundational paper, no pharmacokinetic study exists in any species, and claimed selectivity is preferential rather than absolute. The sharpest caveat is no longer theoretical. A 2023 Circulation study found that clearing senescent cells — with FOXO4-DRI by name, as well as with the small-molecule senolytic ABT-263 — worsened pulmonary haemodynamics in mice, raising right ventricular systolic pressure and hypertrophy and markedly depleting pulmonary endothelial cells, which make up about 30% of lung senescent cells under normal oxygen. That is the drug doing exactly what it is designed to do, in a tissue where the senescent population was load-bearing. The concern about senolysis is therefore not only off-target apoptosis; it is on-target clearance in the wrong place. The broader senolytic field has moved forward primarily with small molecules (dasatinib + quercetin, fisetin, navitoclax) that have entered clinical trials; FOXO4-DRI has not. Any self-experimentation dose is extrapolated from mouse data that does not translate to humans.
History & Discovery
FOXO4-DRI was designed and characterized by Peter de Keizer's group at Erasmus MC in Rotterdam and published in a 2017 paper in Cell that became a landmark reference in the emerging senolytic field. The research question was why senescent cells — damaged cells that stop dividing but persist and secrete inflammatory signals (the SASP) — resist the apoptotic fate that would normally clear them. De Keizer and colleagues identified an interaction between FOXO4 and p53 in senescent cells that sequesters p53 in the nucleus and away from mitochondria, preventing the mitochondrial apoptosis pathway from triggering. They then designed a peptide to competitively disrupt that interaction. The peptide uses a D-retro-inverso design: the amino acid sequence is reversed and all L-amino acids are replaced with D-enantiomers. This structural trick preserves side-chain topology for binding while making the peptide almost entirely resistant to proteolytic degradation, substantially extending in-vivo availability. The headline results are worth stating precisely, because they are routinely merged. The restoration of fitness, fur density and renal function was reported in the fast-ageing XpdTTD/TTD strain and in naturally aged mice; the doxorubicin-treated animals showed neutralisation of chemotoxicity, which is a different claim. Even within the ageing results the running-wheel fitness gain belongs to XpdTTD/TTD — in naturally aged mice the paper records that variation in running-wheel activity was too large for meaningful measurement, with fur density and responsiveness carrying the functional signal instead. One safety comparison from that paper has aged well and is rarely quoted: pan-BCL senolytics such as ABT-263 are limited by severe thrombocytopenia, whereas platelet levels before and 30 days after FOXO4-DRI treatment were not noticeably affected. The translation from that 2017 mouse data to any human clinical program has not occurred. No Phase I, Phase II, or Phase III trials of FOXO4-DRI have been conducted. A small number of additional preclinical studies have explored specific tissue contexts — keloid fibroblasts, pulmonary fibrosis, aged Leydig cells, in vitro chondrocytes, aged testis — but the translational gap from rodent and in-vitro findings to human therapeutic use remains complete. Nevertheless, FOXO4-DRI entered the research-chemical longevity-enthusiast market within a few years of the Cell paper and is used in self-experimentation protocols well outside any clinical framework. What has moved since 2017 is the structural and medicinal chemistry rather than the clinical program. A 2025 Nature Communications paper from Bourgeois, Madl, de Keizer and colleagues identified the disordered p53 transactivation domain as the specific region FOXO4 and FOXO4-DRI engage, putting a structural basis under a mechanism that had been inferred pharmacologically. That paper comes with commercial context the field should not skip: it was partly funded by Cleara Biotech, de Keizer and a co-author hold shares in the company, and the authors hold a published patent whose subject is explicitly the binding and structural studies reported in the manuscript. It is excellent work, but it is not independent confirmation. Independent structural work does exist and reaches a less tidy conclusion — a separate 2025 Nature Communications study from a Czech NMR group reported that the FOXO4-p53 interaction is highly heterogeneous, with p53 retaining substantial flexibility and apparently engaging through multiple binding modes. That work has fed successor molecules, though the successor story is older than it looks: Le and colleagues at OHSU published ES2 in EBioMedicine in 2021, a rationally modelled FOXO4 mimetic that disrupts FOXO4-TP53 foci and preferentially binds FOXO4 over TP53, and reported that intratumoural ES2 plus a BRAF inhibitor produced a survival advantage in mouse melanoma models while repeated systemic delivery to older mice reduced senescent cell numbers in the liver with minimal toxicity — in-vivo data that the newer compounds do not yet match. Kang and colleagues (Journal of Medicinal Chemistry, 2025) later reported CPP-CAND, a shorter conventional L-amino-acid peptide inhibitor of the FOXO4-p53 interaction that they characterize as more selective than FOXO4-DRI and active against cancer cells driven into senescence by doxorubicin and cisplatin. In parallel, an oncology-adjuvant use has appeared in which the peptide is not the therapy but the cleanup crew — clearing the senescent cells chemotherapy leaves behind, as in a 2026 Molecular Carcinogenesis glioblastoma study where FOXO4-DRI improved temozolomide efficacy in cell experiments. None of these successor compounds has entered human trials either.
How It Works
FOXO4-DRI works by blocking a protective signal that keeps damaged old cells alive. When this signal is disrupted, the body's natural cleanup processes can remove these harmful cells, potentially reducing inflammation and improving tissue function.
FOXO4-DRI is a D-retro-inverso peptide that binds the disordered transactivation domain of p53, competing with endogenous FOXO4. In senescent cells, FOXO4 holds p53 in nuclear foci, which keeps it from doing its apoptotic job — the Cell commentary accompanying the original paper described it as FOXO4 protecting senescent-cell viability by keeping p53 sequestered in nuclear bodies. The precise consequence of disrupting that interaction is p53 nuclear exclusion rather than simple release: Baar and colleagues reported that in senescent cells the peptide selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis, and four of this page's other citations use the same nuclear-exclusion language. Work in senescent endothelial cells filled in the downstream steps — co-immunoprecipitation showed FOXO4-DRI preventing FOXO4 from binding p53, facilitating nuclear export of phosphorylated p53, which then triggers BAX and cleaved caspase-3. Two structural refinements from 2025 matter for anyone evaluating the molecule. First, the cell-penetrating tag is not merely a delivery vehicle: the structural study found that both the FOXO4-derived region and the cationic cell-permeability peptide contribute to the interaction with p53, so a truncated or substituted CPP segment is a pharmacological change, not a cosmetic one. The same work found that p53 phosphorylation enhances affinity for both FOXO4 and FOXO4-DRI, implying potency should vary with the DNA-damage state of the tissue. Second, an independent NMR group reported that the FOXO4-p53 interaction is structurally plastic rather than a single clean pose — the p53 transactivation domain retains substantial flexibility in the complex and appears to engage FOXO4 through multiple binding modes. The interaction is real and druggable; it is not a lock-and-key site.
Evidence Snapshot
Human Clinical Evidence
None. Not merely limited — absent. A PubMed search for FOXO4-DRI returns 19 records as of November 2026, every one of them preclinical, in-vitro or review; there is no published human case report, and ClinicalTrials.gov returns no study of the peptide under any name. Self-experimentation accounts circulate in longevity communities, but they are anecdote rather than data and none has been written up.
Animal / Preclinical
Substantial, and broader than the famous paper alone. Baar 2017 reported restored fitness, fur density and renal function in the fast-ageing XpdTTD/TTD strain and in naturally aged mice — the running-wheel fitness gain belongs to XpdTTD/TTD, since variation in naturally aged animals was too large to measure — while the doxorubicin-treated mice showed neutralisation of chemotoxicity rather than that triad. At least five groups with no overlap with the original authors have since reproduced senolytic effects in vivo: bleomycin lung fibrosis (twice, independently), NSCLC radiosensitisation, neonatal hyperoxic lung injury, aged Leydig cells, and the aorta. One in-vivo result points the other way: in Circulation in 2023, FOXO4-DRI worsened pulmonary haemodynamics by clearing senescent pulmonary endothelial cells.
Mechanistic Rationale
Strong. The FOXO4-p53 axis in senescent cells is well-characterized, and the D-retro-inverso design provides protease resistance.
Research Gaps & Open Questions
What the current literature has not yet settled about FOXO4-DRI:
- 01No human clinical trials of any phase have been conducted. Human safety, dosing, pharmacokinetics, pharmacodynamics, and efficacy are all unestablished.
- 02Selectivity of senescent-cell clearance in humans — mouse data showed preferential targeting, but the extent to which this selectivity holds at different doses, across different human tissues, and in different disease states is unknown.
- 03Long-term consequences of senescent-cell clearance — senescent cells play roles in wound healing, tumor suppression, and tissue remodeling, and aggressively clearing them may carry consequences the short-term mouse studies did not capture. This is no longer purely hypothetical: a 2023 Circulation study found that clearing senescent cells with FOXO4-DRI or ABT-263 worsened pulmonary haemodynamics in mice by depleting senescent pulmonary endothelial cells. Which tissues depend on a resident senescent population, and at what ages, is unmapped.
- 04Whether the pulmonary-vascular harm signal generalises beyond the models in which it was found, and whether it is dose- or schedule-dependent. The same on-target clearance improved aortic function in naturally aged and progeroid mice while worsening pulmonary haemodynamics in pulmonary-hypertension models — systemic and pulmonary vascular beds appear to respond in opposite directions, and nothing identifies in advance which other tissues sit on which side of that line.
- 05Comparative performance versus small-molecule senolytics — dasatinib + quercetin, fisetin, and navitoclax have progressed into human trials, and FOXO4-DRI has not; head-to-head data is absent.
- 06Independent replication of the original ageing endpoints specifically. Senolytic activity itself has now been reproduced in vivo by at least five groups with no author overlap with the originating lab — two separate bleomycin lung-fibrosis studies, NSCLC radiosensitisation, neonatal hyperoxic lung injury, aged Leydig cells, and aortic ageing. What has not been independently repeated is the headline experiment: the restoration of fur density, renal function and running-wheel activity in aged and fast-ageing mice. The replication base is broader than it is usually described, and narrower where it matters most.
- 07Pharmacokinetics of D-retro-inverso peptides in humans — distribution, tissue penetration, elimination, and immunogenicity of this structural class are characterized in animal models but not in humans for FOXO4-DRI specifically.
- 08Whether disrupting the FOXO4-p53 interaction compromises p53-dependent tumor surveillance. A 2026 Antioxidants review of FOXO4 redox biology states plainly that clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance — none of which has been done. This is the single most consequential unanswered safety question for the compound.
- 09Whether the senolytic-adjuvant use in oncology generalizes. The in-vivo question is partly answered: FOXO4-DRI radiosensitised NSCLC in vivo as well as in vitro while reducing radiation-induced pulmonary fibrosis (JCI Insight 2021). What remains open is whether the benefit holds across tumour types and schedules — the glioblastoma result (Mol Carcinog 2026) is a cell-culture experiment in which the peptide served as one of two tool compounds, and CPP-CAND against doxorubicin- and cisplatin-senescent cells (J Med Chem 2025) is also in vitro. The countervailing possibility, that clearing therapy-induced senescent cells removes a growth-arrested population acting as a brake, has not been excluded.
- 10Whether next-generation FOXO4-p53 inhibitors outperform FOXO4-DRI. CPP-CAND is shorter, built from conventional L-amino acids, and reported as more selective, but no head-to-head in-vivo comparison with FOXO4-DRI has been published and neither compound has human data.
Forms & Administration
FOXO4-DRI is typically discussed in the context of subcutaneous injection, though no published study has used that route — the mouse literature is intravenous and intraperitoneal. Due to its D-amino acid composition, it has enhanced stability compared to L-peptides. Protocols are highly experimental. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no validated human dose. The de Keizer mouse studies used 5 mg/kg given three times on alternate days (day 1, 3 and 5) — and the route was intravenous in the chemotoxicity experiments and intraperitoneal in others, never subcutaneous. The Baar 2017 figure legend reads “FOXO4-DRI: 3x i.v. at 5mg/kg, every other day (day 1, 3 and 5)”, and where intraperitoneal dosing was used the paper says so explicitly, for comparability with a drug given that way. Community self-experimentation protocols have extrapolated these to human mg-range doses (commonly described figures are in the range of 2–5 mg per injection), but direct mg/kg translation from mouse to human is not pharmacologically justified without clinical data, and the appropriate human dose is genuinely unknown.
Frequency
Preclinical mouse protocols typically used a short course of 3 doses over about a week, sometimes repeated at intervals of weeks to months. The senolytic concept is pulse-dosing rather than chronic dosing — the goal is to clear a population of senescent cells, not to maintain continuous receptor activation. Community self-experimentation mirrors this, typically describing single or few-dose protocols rather than daily use.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
If any convention has emerged, it is widely spaced pulses (every several weeks to months) rather than continuous cycling. There is no human-data basis for any specific schedule.
Protocol Notes
FOXO4-DRI is typically supplied as a lyophilized powder and reconstituted in bacteriostatic water. The D-retro-inverso design provides substantial proteolytic stability, meaning reconstituted peptide is relatively robust compared with L-peptides. It is worth being precise about route, because the community convention and the published evidence diverge: the peptide is sold and discussed for subcutaneous injection, but the word subcutaneous does not appear anywhere in Baar 2017, and no published study has administered FOXO4-DRI by that route in any species. Everything known about its activity comes from intravenous or intraperitoneal dosing. The core honest statement about dosing is that nothing is validated in humans. The self-experimentation community extrapolates mouse doses, adjusts for perceived tolerability, and shares anecdotes. Those anecdotes are not evidence. Known risks include the theoretical possibility of off-target apoptosis in cell populations that are not actually senescent — tissue-specific selective clearance was demonstrated in mouse models, but the fidelity of that selectivity at different doses in humans, across different tissues and disease states, has not been established. The senolytic field as a whole is moving forward with clinical trials (dasatinib + quercetin, navitoclax, UBX-series compounds), but FOXO4-DRI specifically has not been part of those programs.
FOXO4-DRI has never been tested in humans in any controlled trial. It is not FDA-approved. Any dose figures circulating in the community are extrapolated from mouse studies and are not validated. Mouse does not equal human — this is not a cliché; it is the central caveat.
Timeline of Effects
Onset
In the 2017 mouse studies, loss of senescent-cell markers and restoration of functional measures (physical activity, fur density, renal function) was documented over several weeks following a multi-dose treatment course. Whether any comparable time-course applies to humans is unknown.
Peak Effect
The senolytic framework proposes a durable effect after each clearance pulse, as long as the senescent-cell population remains cleared. In mice, functional improvements were sustained for weeks to months after a single treatment course, but eventually required re-dosing as new senescent cells accumulated. No human data characterizes this cycle.
After Discontinuation
No pharmacokinetic study of FOXO4-DRI has been published in any species — the words half-life and pharmacokinetics do not appear in the foundational paper, and no elimination figure for this peptide exists to quote. The conceptual model is that the peptide clears and its direct pharmacologic effect ends relatively quickly even allowing for enhanced D-peptide stability, but the biological effect — having cleared a cell population — persists until those cells are regenerated through normal aging processes. Whether this model is accurate in humans is not demonstrated.
Common Questions
What are senescent cells?
Senescent cells are damaged or aged cells that stop dividing but don't die. They accumulate with age and release inflammatory molecules (SASP) that can damage nearby healthy tissue, contributing to aging and age-related diseases.
Is FOXO4-DRI available for human use?
No, in a stronger sense than usual. FOXO4-DRI is a research compound that has never been administered to a human in any registered study — ClinicalTrials.gov returns nothing for the peptide under any name, and the indexed literature contains no case report. It is not approved by any regulator. It is sold through research-chemical channels labelled not for human use, and anyone taking it is doing so with no human safety data, no human dose, and no published pharmacokinetics in any species.
Can clearing senescent cells ever be harmful?
Yes, and the clearest example involves this peptide. Senescent cells are usually described as metabolic debris, but in some tissues they are doing necessary work. A 2023 Circulation study set out to test senolysis in pulmonary hypertension and found that clearing senescent cells — genetically, with the small molecule ABT-263, and with FOXO4-DRI by name — made the disease worse: right ventricular systolic pressure and hypertrophy rose, vessel remodelling increased, and pulmonary endothelial cells were markedly depleted. Those endothelial cells account for roughly 30% of lung senescent cells under normal oxygen. The authors concluded that eliminating senescent pulmonary endothelial cells may worsen pulmonary haemodynamics, and invited the field to consider the impact on pulmonary vessels of any senescence-controlling strategy. The result is notable because it is not a selectivity failure — better targeting would not have helped. It also sits alongside a 2025 study in which the same peptide improved aortic function in aged and progeroid mice, so the systemic and pulmonary circulations appear to respond in opposite directions.
Are newer FOXO4-p53 peptides being designed to replace FOXO4-DRI?
Yes, and the first of them is older than most summaries suggest. In 2021 a group at OHSU published ES2, a rationally modelled FOXO4 mimetic that disrupts FOXO4-TP53 foci and binds FOXO4 in preference to TP53; intratumoural ES2 combined with a BRAF inhibitor produced a survival advantage in mouse melanoma models, and repeated systemic dosing in older mice reduced senescent cell numbers in the liver with minimal toxicity. The structural work has continued in parallel: a 2025 Nature Communications paper from the originating group mapped the disordered p53 transactivation domain as the binding target of both FOXO4 and FOXO4-DRI, while a separate 2025 Nature Communications study from an independent NMR group found the same interaction to be structurally heterogeneous, with p53 apparently engaging through multiple binding modes rather than one pose. A 2025 Journal of Medicinal Chemistry paper described CPP-CAND, a shorter L-amino-acid peptide inhibitor of the FOXO4-p53 interaction that the authors report as more selective than FOXO4-DRI and active against cancer cells pushed into senescence by doxorubicin and cisplatin. The design logic is notable: FOXO4-DRI's D-retro-inverso backbone buys proteolytic stability but complicates manufacturing and clearance, and the newer compounds trade some of that stability for a conventional L-peptide that is easier to make and characterize. None of these successors has entered human trials either — they are earlier in development than FOXO4-DRI, not further along.
Is FOXO4-DRI being studied in cancer?
It appears in cancer research, but as an adjuvant rather than as a cancer drug, and the thread is older than it is usually credited. Chemotherapy and radiation push surviving tumor cells into senescence, and those senescent cells secrete inflammatory signals (the SASP) that may support tumor regrowth. A JCI Insight study in 2021 reported that FOXO4-DRI selectively killed senescence-like cancer-associated fibroblasts, radiosensitised non-small-cell lung cancer both in cell culture and in live mice, and separately alleviated radiation-induced pulmonary fibrosis — so in-vivo adjuvant data has existed since 2021, not merely cell-culture data. The 2026 Molecular Carcinogenesis glioblastoma work is in vitro, and used FOXO4-DRI as one of two tool compounds to demonstrate that clearing temozolomide-induced senescent cells improves chemotherapy efficacy. None of this is clinical practice, and it cuts both ways for anyone considering self-experimentation: the same p53-releasing mechanism that makes the peptide useful as an oncology adjuvant in a controlled setting is the reason a recent review flagged the need for explicit assessment of p53-dependent tumor surveillance before any human use.
Who FOXO4-DRI Is NOT For
- •Any cancer history — apoptosis-triggering peptides are pharmacologically adjacent to oncology therapeutics, and the interactions with active tumor biology, chemotherapy regimens, and post-cancer surveillance are not characterized.
- •Pregnancy and breastfeeding — no safety data of any kind; a peptide designed to trigger apoptosis in a specific cell population is categorically unsuitable for use during pregnancy or lactation absent rigorous reproductive toxicology.
- •Pediatric use (under 18) — no data and no appropriate indication; the senescent-cell burden in pediatric populations is categorically different from the aging context FOXO4-DRI was designed for.
- •Active autoimmune disease — senescent cells and the SASP interact with immune surveillance in ways that are not fully understood; perturbing this system with an off-label senolytic in active autoimmunity is imprudent.
- •Recent surgery or active wound healing — senescent cells play a transient role in wound healing, and senolytic pulses during active repair have not been studied for safety.
- •Pulmonary hypertension or known pulmonary vascular disease — the most specific documented harm signal for this peptide. In a 2023 Circulation study, clearing senescent cells with FOXO4-DRI worsened pulmonary haemodynamics in mice and markedly depleted pulmonary endothelial cells, and the authors explicitly caution that senolytic strategies may worsen pulmonary haemodynamics.
- •Known hypersensitivity to peptide therapeutics, D-peptides, or excipients used in reconstitution.
Drug & Supplement Interactions
Clinical drug interaction data for FOXO4-DRI is completely absent because no human clinical studies have been conducted. What follows is mechanistic speculation. The highest-risk theoretical interaction is with chemotherapy. The 2017 Cell paper demonstrated that FOXO4-DRI could clear therapy-induced senescent cells in mice receiving doxorubicin, but in a controlled preclinical protocol — outside that protocol, overlapping a senolytic with active cytotoxic chemotherapy in humans has not been safety-characterized, and off-target apoptosis in damaged-but-not-senescent cell populations is a real concern. Overlap with other senolytics (dasatinib + quercetin, fisetin, navitoclax) in combination is not studied and theoretically risks broader off-target apoptosis. One contrast within that class is worth stating, because it runs in the peptide's favour: the pan-BCL senolytics ABT-263 and ABT-737 are limited clinically by severe thrombocytopenia, and the foundational study found platelet counts unchanged 30 days after FOXO4-DRI. That is a real difference in haematologic risk — but it did not prevent the two agents from producing the same pulmonary-vascular harm in the 2023 Circulation study, where ABT-263 and FOXO4-DRI both worsened pulmonary haemodynamics. Shared mechanism, shared risk, different side-effect profiles. Immunosuppressive medications interact with senescent-cell immune surveillance in complex ways. Anti-inflammatory medications may interact with the SASP-related effects the peptide is meant to attenuate. Patients on any active medication should disclose FOXO4-DRI use to their prescribing clinicians, and patients with any oncology history should not use the peptide outside a proper clinical research context.
Safety Profile
Common Side Effects
Cautions
- • Very limited human data
- • Not FDA-approved
- • Complex mechanism requires expert guidance
- • Potential for unintended cell death
What We Don't Know
Nearly all data comes from animal models. Human safety, dosing, and long-term effects are essentially unknown.
Legal Status
United States
FOXO4-DRI is not FDA-approved for any medical indication. It has never entered human clinical trials. It is sold through research-chemical suppliers labeled 'not for human use'; distribution for human consumption is unauthorized under the FD&C Act. It is not a scheduled controlled substance.
International
Not authorized as a medicine in the EU, UK, Canada, or Australia. Regulatory posture across developed markets treats it as an unapproved investigational agent.
Sports & Competition
FOXO4-DRI is not listed by name on the WADA Prohibited List. However, WADA category S0 prohibits any substance 'not currently approved by any governmental regulatory health authority for human therapeutic use' — a description that covers FOXO4-DRI. Athletes subject to WADA, USADA, UKAD, or equivalent frameworks should treat it as prohibited in and out of competition under S0, regardless of whether the specific peptide is named.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
FOXO4-DRI has been shown to reverse aging.
Reality
Mouse studies showed restoration of specific functional measures — physical activity, fur density, renal function — in aged and chemotherapy-treated mice. That is scientifically interesting. It is not 'reversing aging' in a comprehensive sense, and it is not a human finding. Extrapolating a headline-worthy rodent result into a claim about human aging reversal is not what the data supports.
Myth
The D-retro-inverso design makes FOXO4-DRI safe for long-term use in humans.
Reality
The DRI modification makes the peptide resistant to proteolytic degradation and extends in-vivo availability. It does not address the underlying pharmacologic and biological safety questions — off-target apoptosis, dose-response in humans, interactions with active disease processes, long-term immune and tissue consequences of repeated senolytic pulses. Stability is not safety.
Myth
If the mouse data looks this good, human data must be just around the corner.
Reality
The original paper was published in 2017. As of the most recent public information, no human clinical trial of FOXO4-DRI has been registered or initiated. The senolytic field is moving forward, but largely through small molecules rather than this specific peptide. 'Just around the corner' has been the framing for years, and it remains speculative.
Myth
FOXO4-DRI available from research-chemical suppliers is the same as what was used in the Erasmus MC studies.
Reality
The published studies used peptide produced under research-grade standards with identity, purity, and endotoxin specifications. Research-chemical market supply does not consistently meet those specifications, and misidentification or truncation of D-peptides is a documented market issue. Assuming equivalence is not warranted.
Myth
Because FOXO4-DRI selectively clears senescent cells, there is no meaningful risk to healthy cells.
Reality
Selectivity in the 2017 mouse data was preferential rather than absolute, and it was characterized at specific doses in specific biological contexts. Scaling to different doses, different tissues, different human disease states, and different concurrent therapies may change the selectivity profile in ways that have not been measured. Treating preferential selectivity as categorical safety is unsupported.
Myth
The only safety worry with a senolytic is that it might kill healthy cells by mistake.
Reality
That framing misses the harder problem, which is the drug working correctly. In Circulation in 2023, clearing senescent cells — with FOXO4-DRI by name, and independently with the small molecule ABT-263 — made pulmonary hypertension worse in mice, raising right ventricular pressure and hypertrophy while markedly depleting pulmonary endothelial cells. Those endothelial cells are roughly 30% of the lung's senescent cells under normal oxygen, and removing them was the mechanism of harm, not a failure of targeting. Senescent cells are not uniformly waste; in some tissues they are doing load-bearing work. Perfect selectivity would not have prevented this result.
Published Research
19 studiesFOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting
Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
Naunyn-Schmiedeberg Arch Pharmacol 2026. Listed for completeness and flagged for caution rather than endorsed. It attributes to FOXO4-DRI a set of outcomes — restored cerebral blood flow and blood-brain-barrier integrity, reversed hippocampal atrophy, clearance of amyloid-beta and pathological tau — that are not traceable to FOXO4-DRI in the primary literature; those endpoints come from other senolytic approaches. It also describes high-dose fisetin as a FOXO4-axis modulator, which is not an accurate characterisation. A reader encountering the brain-ageing claims circulating about this peptide will usually be encountering this review at one remove.
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Front Bioeng Biotechnol 2025. An in-vivo ageing result from a group unconnected to the original lab: injection of FOXO4-DRI in both naturally aged and progeroid mice suppressed aortic ageing and improved aortic function. It also supplies the downstream mechanism the foundational paper left implicit — co-immunoprecipitation showed the peptide preventing FOXO4 from binding p53, facilitating nuclear export of phosphorylated p53, which then triggers BAX and cleaved caspase-3. Worth reading directly against the Circulation pulmonary-hypertension result, since the two describe the same on-target action helping systemic arteries and harming pulmonary ones.
Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Bourgeois, Madl, de Keizer and colleagues, Nature Communications 2025. Put a structural basis under the mechanism, identifying the disordered p53 transactivation domain as the region engaged, and added two details with practical consequences: the cationic cell-permeability tag contributes to the interaction rather than merely delivering the peptide, and p53 phosphorylation increases affinity for both FOXO4 and FOXO4-DRI. Read it with the funding statement in view — the work was partly funded by Cleara Biotech, de Keizer and a co-author hold shares, and the binding and structural studies reported are the subject of a published patent. It is the originating group plus its commercial vehicle, not independent replication.
Structural plasticity of the FOXO-DBD:p53-TAD interaction
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born and colleagues, Circulation 2023 — the most important safety result for this peptide, and it is not an off-target effect. Senescent-cell clearance, achieved both genetically and pharmacologically with ABT-263 and FOXO4-DRI by name, raised right ventricular systolic pressure and hypertrophy, increased vessel remodelling and markedly depleted pulmonary endothelial cells, which constitute about 30% of lung senescent cells in normoxia. The authors conclude that eliminating senescent pulmonary endothelial cells by senolytic interventions may worsen pulmonary haemodynamics, and invite consideration of the impact on pulmonary vessels of any strategy aimed at controlling senescence. For a compound sold for unsupervised use, this is the single most consequential finding in the literature.
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway
Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis
JCI Insight 2021. The paper that dates the oncology-adjuvant thread five years earlier than it is usually credited, and takes it further: FOXO4-DRI selectively killed senescence-like cancer-associated fibroblasts, radiosensitised NSCLC both in vitro and in vivo, and separately alleviated radiation-induced pulmonary fibrosis in vivo. Independent of the originating group.
Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Front Bioeng Biotechnol 2021. Frequently cited on peptide pages for the title alone, which is why the second half of the result matters: the peptide did selectively remove senescent cells from expanded human chondrocytes, but pre-treatment did not enhance the chondrogenic potential of those cells, and the authors state that its utility in promoting cartilage formation needs further investigation. Clearing senescent cells and restoring function are not the same endpoint, and this paper is the cleanest demonstration of the gap.
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Rejuvenation by Therapeutic Elimination of Senescent Cells
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
The foundational 2017 Cell paper from Peter de Keizer's group that introduced FOXO4-DRI and demonstrated restored physical fitness, fur density, and renal function in aged and chemotherapy-treated mice. Every subsequent FOXO4-DRI paper builds on this work.
Quick Facts
- Class
- Senolytic Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 19PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.